ArticleClinical kidney journal2021
Immunosuppression minimization in kidney transplant recipients hospitalized for COVID-19.
Article in Clinical kidney journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Serological responses and clinical outcomes following a three-dose primary COVID-19 vaccine schedule in kidney transplant recipients and people on dialysis.Clinical & translational immunology · 2024Article
- Kidney Allograft Rejection and Coronavirus Disease 2019 Infection: A Narrative Review.Advanced biomedical research · 2023Review
- [Update of the recommendations on the management of the SARS-CoV-2 coronavirus pandemic (COVID-19) in kidney transplant patients.]Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia · 2022Review
- Immune responses to SARS-CoV-2 in dialysis and kidney transplantation.Clinical kidney journal · 2022Review
- SARS-CoV-2 Vaccination in Solid-Organ Transplant Recipients.Vaccines · 2022Review
- Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?Viruses · 2022Review
- COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic.BMC nephrology · 2022Article
- Understanding the Risks of Immunosuppression Reduction for Active COVID-19 Infection.Kidney international reports · 2022Article
- Occurrence ofKidney international reports · 2022Article
- [Management of immunosuppressive therapy in kidney transplant recipients with COVID19. A multicentre national study derived form the S.E.N. COVID registry.]Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia · 2022Article
- Late antibody-mediated rejection in a kidney transplant recipient: COVID 19 induced?BMC nephrology · 2022Article
- Immunosuppression and SARS-CoV-2 Infection in Kidney Transplant Recipients.Transplantation direct · 2022Review
- Recovery of kidney function after AKI because of COVID-19 in kidney transplant recipients.Transplant international : official journal of the European Society for Organ Transplantation · 2021Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunosuppressed patients such as kidney transplant recipients (KTs) have increased mortality risk in the setting of coronavirus disease 2019 (COVID-19). The role and management of chronic immunosuppressive therapies during COVID-19 must be characterized.
methodsHerein, we report the follow-up of a cohort of 47 KTs admitted at two Spanish Kidney Transplant Units, who survived COVID-19. The impact of the management of immunosuppression during COVID-19 on graft function and immunologic events was evaluated.
resultsAt least one immunosuppressive agent was withdrawn in 83% of patients, with antimetabolites being the most frequent. Steroids were generally not stopped and the dose was even increased in 15% of patients as part of the treatment of COVID-19. Although immunosuppressive drugs were suspended during a median time of 17 days, no rejection episodes or
conclusionsOur observational study suggests that immunosuppression in KTs hospitalized due to COVID-19 could be safely minimized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.